Showing results (1061-1070 of 1,094) with videos related to

Sort By:
Pageof 110
Bioorganic & Medicinal Chemistry Letters|November 10, 2009
Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577Yan Shi, Chi Li, Stephen P O'Connor, et al.
Plos One|March 9, 2023
Standardization of flow cytometry and cell sorting to enable a transcriptomic analysis in a multi-site sarcoidosis studyRoman E Magallon, Laura D Harmacek, Nicholas K Arger, et al.
Bioorganic & Medicinal Chemistry Letters|November 2, 2011
Arylsulfonamidopiperidone derivatives as a novel class of factor Xa inhibitorsYan Shi, Stephen P O'Connor, Doree Sitkoff, et al.
Breast Cancer Research : BCR|July 12, 2014
Peroxiredoxin-1 protects estrogen receptor α from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancerPatrick C O'Leary, Marta Terrile, Malgorzata Bajor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2019
BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast CancerLouise Walsh, Kathryn E Haley, Bruce Moran, et al.
ACS Medicinal Chemistry Letters|July 23, 2014
Optimization of 1,2,4-Triazolopyridines as Inhibitors of Human 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD-1)Jun Li, Lawrence J Kennedy, Haixia Wang, et al.
Cancer Research|April 30, 2017
Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast CancerBo Li, Triona Ni Chonghaile, Yue Fan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2020
Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast CancerDenis M Collins, Stephen F Madden, Nicola Gaynor, et al.
NPJ Genomic Medicine|May 29, 2024
Analysis of cell free DNA to predict outcome to bevacizumab therapy in colorectal cancer patientsTom Venken, Ian S Miller, Ingrid Arijs, et al.
Bioorganic & Medicinal Chemistry Letters|October 11, 2005
Ketene aminal-based lactam derivatives as a novel class of orally active FXa inhibitorsYan Shi, Jing Zhang, Philip D Stein, et al.
Pageof 110